phase iii study of lutetium-177-psma-617 in patients with metastatic castration-resistant prosta...
Published 3 years ago • 5.3K plays • Length 6:24Download video MP4
Download video MP3
Similar videos
-
4:41
lutetium-177–psma-617 improves self-reported pain and hrqol in taxane-naïve patients with psma-p...
-
11:07
phase 3 vision study of 177lupsma 617 for metastatic castration-resistant prostate cancer
-
4:48
vision: lu-177-psma-617 in mcrpc
-
2:24
eclipse - a randomized phase 3 trial for 177-lu-psma-i&t in patients with mcrpc
-
0:28
177lu-psma-617 for metastatic castration-resistant prostate cancer
-
11:01
lutetium-177: psma guided treatment | #prostatecancer | #markscholzmd | #pcri
-
3:03
vision: tolerability of 177lu-psma-617 by treatment exposure in patients with mcrpc
-
7:14
vision study
-
5:30
fractionated dose 177lu-psma-617 in patients with mcrpc
-
4:16
lutetium-177 psma scanning for prostate cancer
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
1:28
vision: 177lu-psma-617 in psma-positive mcrpc
-
4:28
upfront [177lu]lu-psma-617 radioligand therapy prior to radical prostatectomy in men with hr pc
-
4:08
lu-177 psma-617 versus vs cabazitaxel: therap trial @ snmmi 2021
-
5:06
efficacy of lutetium-177–psma-617 for advanced prostate cancer
-
1:35
vision: safety analysis of 177lu-psma-617 in mcrpc
-
3:56
vision: 177lu-psma-617 in psma-positive mcrpc
-
5:37
177lu-psma-617 for the early treatment of prostate cancer
-
1:02
dr. gafita on prognostic models for treatment with 177lu-psma-617 in mcrpc